---
title: "Imbruvica (ibrutinib), all indications: Pharmacology questions"
description: "Pharmacology questions on Imbruvica (ibrutinib) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: How does Imbruvica work (mechanism of action)? How is Imbruvica metabolized and eliminated? What is the half-life of Imbruvica? Does food affect Imbruvica levels? 1 further question follow. 5 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/imbruvica/pharmacology"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Imbruvica (ibrutinib), all indications: Pharmacology questions

Manufacturer: Pharmacyclics LLC; Janssen Biotech, Inc.  
Prescribing information: [Imbruvica](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf)  
Indication pages: [Chronic lymphocytic leukemia and small lymphocytic lymphoma](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma)

## Mechanism

<a id="imbruvica-mechanism"></a>

### How does Imbruvica work (mechanism of action)?

> “Ibrutinib is a small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Ibrutinib forms a 
> covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK 
> enzymatic activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and 
> cytokine receptor pathways. BTK’s role in signaling through the B-cell surface receptors results 
> in activation of pathways necessary for B-cell trafficking, chemotaxis, and adhesion. Nonclinical 
> studies show that ibrutinib inhibits malignant B-cell proliferation and survival in vivo as well as 
> cell migration and substrate adhesion in vitro.”

Source: [IMBRUVICA: Prescribing information, page 34, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=34)

> “IMBRUVICA<sup>®</sup> (ibrutinib) inhibits BTK to disrupt 3 key B-cell processes*
>
> 1. Inhibits proliferation and survival<sup>1-6</sup>
>
> 2. Inhibits adhesion<sup>1,6-11</sup>
>
> 3. Modulates chemotaxis and trafficking<sup>1,5,7,9,11-13</sup>
>
> <sup>*</sup>As demonstrated by in vitro and in vivo studies.”

Source: [IMBRUVICA: Mechanism of Action - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/mechanism-of-action#:~:text=%28ibrutinib%29%20inhibits%20BTK%20to%20disrupt,vitro%20and%20in%20vivo%20studies.)

## Pharmacokinetics

<a id="imbruvica-metabolism"></a>

### How is Imbruvica metabolized and eliminated?

> “Metabolism is the main route of elimination for ibrutinib. It is metabolized to several metabolites 
> primarily by cytochrome P450 (CYP) 3A and to a minor extent by CYP2D6. The active 
> metabolite, PCI-45227, is a dihydrodiol metabolite with inhibitory activity towards BTK 
> approximately 15 times lower than that of ibrutinib. The range of the mean metabolite to parent 
> ratio for PCI-45227 at steady-state is 1 to 2.8.”

Source: [IMBRUVICA: Prescribing information, page 35, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=35)

> “Ibrutinib, mainly in the form of metabolites, is eliminated primarily via feces. After a single oral 
> administration of radiolabeled ibrutinib, 90% of radioactivity was excreted within 168 hours,”

Source: [IMBRUVICA: Prescribing information, page 35, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=35)

> “with 80% excreted in the feces and less than 10% eliminated in urine. Unchanged ibrutinib 
> accounted for 1% of the radiolabeled excreted dose in feces and none in urine, with the 
> remainder of the excreted dose being metabolites.”

Source: [IMBRUVICA: Prescribing information, page 36, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=36)

<a id="imbruvica-half-life"></a>

### What is the half-life of Imbruvica?

> “Intravenous clearance was 62 L/h in fasted conditions and 76 L/h in fed conditions. In line with 
> the high first-pass effect, the apparent oral clearance is 2000 L/h in fasted conditions and 
> 1000 L/h in fed conditions. The half-life of ibrutinib is 4 hours to 6 hours.”

Source: [IMBRUVICA: Prescribing information, page 35, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=35)

> “Ibrutinib is absorbed after oral administration with a median Tmax of 1 hour to 2 hours.”

Source: [IMBRUVICA: Prescribing information, page 35, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=35)

> “Steady-state concentrations of ibrutinib without 
> CYP3A inhibitors were achieved with an accumulation ratio of 1 to 1.6 after 1 week of multiple 
> daily doses of 420 mg.”

Source: [IMBRUVICA: Prescribing information, page 35, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=35)

<a id="imbruvica-food-effect"></a>

### Does food affect Imbruvica levels?

> “The administration of IMBRUVICA with a high-fat and high-calorie meal (800 calories to 
> 1,000 calories with approximately 50% of total caloric content of the meal from fat) increased 
> ibrutinib Cmax by 2- to 4-fold and AUC by approximately 2-fold, compared with administration 
> of ibrutinib after overnight fasting.”

Source: [IMBRUVICA: Prescribing information, page 35, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=35)

## Components

<a id="imbruvica-inactive-ingredients"></a>

### What are the inactive ingredients in Imbruvica capsules, tablets, and oral suspension?

> “IMBRUVICA (ibrutinib) capsules for oral use are available in the following dosage strengths: 70 
> mg and 140 mg. Each capsule contains ibrutinib (active ingredient) and the following inactive 
> ingredients: croscarmellose sodium, magnesium stearate, microcrystalline cellulose, sodium 
> lauryl sulfate. The capsule shell contains gelatin, titanium dioxide, yellow iron oxide (70 mg 
> capsule only), and black ink.”

Source: [IMBRUVICA: Prescribing information, page 33, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=33)

> “IMBRUVICA (ibrutinib) tablets for oral use are available in the following dosage strengths: 140 
> mg, 280 mg, and 420 mg. Each tablet contains ibrutinib (active ingredient) and the following 
> inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, 
> magnesium stearate, microcrystalline cellulose, povidone, and sodium lauryl sulfate. The film 
> coating for each tablet contains ferrosoferric oxide (140 mg, 280 mg, and 420 mg tablets), 
> polyvinyl alcohol, polyethylene glycol, red iron oxide (280 mg tablets), talc, titanium dioxide, 
> and yellow iron oxide (140 mg and 420 mg tablets).”

Source: [IMBRUVICA: Prescribing information, page 34, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=34)

> “IMBRUVICA (ibrutinib) oral suspension contains 70 mg/mL ibrutinib (active ingredient) and 
> the following inactive ingredients: benzyl alcohol, citric acid monohydrate, disodium hydrogen 
> phosphate, hypromellose, microcrystalline cellulose and carboxymethylcellulose sodium, 
> purified water and sucralose.”

Source: [IMBRUVICA: Prescribing information, page 34, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=34)

## Related pages
- [Medical information: Imbruvica (ibrutinib): All indications](https://www.evicenter.com/medical-information/imbruvica)
- [Indication](https://www.evicenter.com/medical-information/imbruvica/indication)
- [Safety](https://www.evicenter.com/medical-information/imbruvica/safety)
- [Specific populations](https://www.evicenter.com/medical-information/imbruvica/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/imbruvica/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/imbruvica/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/imbruvica/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/imbruvica/access-and-coverage)
